Warning:
Be aware of fake ESCMID Global websites and fraudulent emails. Only use the official ESCMID Global online registration for your bookings.
Search
Frequent searches
Suggestions

AMR Science-Policy Forum

Co-hosted by ESCMID and the Global Leaders Group on Antimicrobial Resistance (GLG), CARB-X, LifeArc, the Novonordisk Foundation and the Gates Foundation.

ESCMID invites you to participate in this joint high-level AMR event co-hosted by ESCMID and the Global Leaders Group on Antimicrobial Resistance (GLG), CARB-X, LifeArc, the Novonordisk Foundation and the Gates Foundation taking place on Friday, 17 April 2026 onsite at ESCMID Global 2026 in Munich, Germany. With the Independent Panel for Evidence for Action against AMR (IPEA) in the making, it is important to move now from commitments into action. Connecting science and policy has never been more important and this meeting aims to bridge that gap.

Preliminary Programme

Under Pressure: Smart Policies for Lean Times

14:00-16:00 CEST - SPF Working Groups

Two parallel Working Groups will lead into the plenary session. Both are open to all ESCMID Global participants and designed to foster interactive, solution-oriented discussions.

1. Evidence for Policy: Modelling and Economics

 

This Working Group will examine how modelling and economic analysis can guide effective AMR policy decisions within a One Health context.

  1. The first part will address the drivers and impacts of AMR and assess the projected effects of potential interventions.
  2. The second part will focus on economic evaluations, including cost-effectiveness and cost–benefit assessments of prevention and treatment.

The session will be highly interactive and structured around six short interventions by invited discussants, followed by open discussion with all participants.

Understanding the global drivers of AMR 
Lulla Opatowski (Institut Pasteur, Paris, France) 

Understanding transmission pathways of AMR and mechanisms driving emergence and cross-sectoral spread 
Patrick Musicha (Malawi liverpool wellcome programme, Blantyre, Malawi) 

Modelling the potential impact of AMR interventions 
Joseph Lewnard (University of California Berkeley, Berkeley, USA) 

What is the national and global economic impact of current AMR trends across One Health sectors 
Julie Robotham (Imperial College London, London, UK) 

Cost-effectiveness/cost-benefit of prevention strategies to mitigate AMR 
Shiela Marie Selisana (Health Intervention and Technology Assessment Program foundation (HITAP), Nonthaburi, Thailand) 

Cost-effectiveness/cost-benefit of treatment strategies to mitigate AMR 
Yiying Cai (Duke-NUS Medical School, Singapore, Singapore)

2. Innovation for Action: Diagnostics and Cost-Effectiveness Across the Product Development and Implementation Pathway

Diagnostics are central to effective AMR mitigation, enabling early detection, targeted treatment, and rational antibiotic use. However, challenges persist across development, evaluation, reimbursement, and implementation - particularly regarding real-world cost-effectiveness, system-level integration, and equitable access.

This Working Group will identify key diagnostic needs, map barriers along the product development and implementation pathway, and propose an evidence-based framework to guide innovation.

The discussion will highlight economic, clinical, and contextual considerations across diverse healthcare settings.
Following a brief introduction, the session will feature six short interventions by invited discussants, followed by an open discussion.

Diagnostics in Context: Innovation, Adaptation, and Barriers to Uptake 
Mirfin Mpundu (ReAct Africa, Lusaka, Zambia) 

Trials That Matter: Evidence-Driven Diagnostics for Health Systems 
Julia Bielicki (University Children's Hospital Basel (UKBB), Basel, Switzerland) 

The social lives of POCT 
Clare Chandler (London School of Hygiene and Tropical Medicine, London, UK) 

Costing the global good of diagnostics 
Chantal Morel (University of Bern, Bern, Switzerland) 

Affordable and accessible solutions - partnerships and challenges! 
Ghada Zoubiane (LifeArc, London, UK)

16:00-16:15 CEST - Coffee break

16:15-18:00 CEST - Session 2
Policy to drive action: Establishing the Independent Panel on Evidence for Action on AMR and updating the Global Action Plan
 

The plenary session will explore the overarching theme AMR Under Pressure: Smart Policies for Lean Times from different perspectives.

Keynote lecture 
How AMR policy action can be strengthened under financial and operational constraints—emphasising opportunities to achieve more with limited resources.
This will be followed by thematic talks covering: 

  1. AMR Policy Action Under Pressure – doing more with less 
    Naomi Rupasinghe (World Bank, Washington, USA) 
     
  2. Efficient and effective IPC 
    Benedetta Allegranzi (WHO, Geneva, Switzerland) 
     
  3. Prevention Pays Off: Vaccination Policies for AMR
    Padmini Srikantiah (Gates Foundation, Seattle, USA) 
     
  4. Global AWaRe targets and national cost savings 
    Koen Pouwels (University of Oxford, Oxford, UK) 
     
  5. A gram of prevention or a kilo of cure? 
    Javier Yugueros-Marcos (World Organisation for Animal Health, Paris, France)


Conclusion
A panel discussion will focus on prioritising cost-effective interventions, aligning national policies with global commitments, and exploring mechanisms for cross-sectoral funding.

18:00 CEST - Networking reception

Partner organisations